跳至主要内容
临床试验/NCT03300739
NCT03300739已完成不适用

Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients

Massachusetts General Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2016年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
Respiratory rate (breaths per minute)

研究概览

简要总结

This is an observational pilot study focused on collecting data on clinical variables that can improve the understanding of potential predictors of disease exacerbation and readmissions in COPD patients. The study aim is to understand how the variability of clinical parameters (respiratory rate, forced expiratory volume in one second, and oxygen saturation), physical activity and quality of life is associated with the risk of exacerbation in COPD patients.

详细描述

The investigational product to be used in this trial is the ResMed Biomotion Sensor (ResMed Sensor Technologies, Dublin, Ireland). This device uses very low power radio waves (~1/100th of the strength of a mobile phone signal) to detect respiratory movements of a person while asleep- without physical contact with the individual. The device is designed to measure up to 5 feet, so that only the person on the side of the bed nearest the device is monitored. Algorithms have been developed to analyze the respiratory movement signals and extract information about respiration rate, bodily movements, sleep/wake patterns and sleep disordered respiration.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Medically stable and ambulatory COPD (primary diagnosis) patients who have had an emergency room visit or hospitalization for an acute exacerbation of COPD within the past 30 days.
  • Sufficient understanding of the English language to be able to read and understand study procedures.

排除标准

  • Currently on admission in the hospital, on non-invasive positive airway pressure ventilation
  • Visual, hearing or cognitive impairments at the discretion of their physician.
  • Currently participating in a COPD telemonitoring program.
  • No AT&T cellular coverage at their primary residence
  • Any other medical or psychological condition that, in the opinion of the investigator may present an unreasonable risk to the study participant as a result of his/her participation in this study, may make participant's participation unreliable, or may interfere with study assessments.

结局指标

主要结局

Respiratory rate (breaths per minute)

时间窗: Daily, 16 weeks

Collected by study device, Reassure Respiration Monitor. This device uses very low power radio waves to detect respiratory movements of a person while asleep.

次要结局

  • Depression(Monthly for 16 weeks)
  • Oxygen saturation (%)(Daily for 16 weeks)
  • Forced Expiratory Volume in 1 Second (FEV1). FEV1 is the volume of air forcefully exhaled in 1 second.(Weekly for16 weeks)
  • Quality of life(Baseline (Day 0) and Close-out (16 weeks))
  • COPD symptom assessment(Weekly for 16 weeks)
  • Physical activity(Daily for 16 weeks)
  • Body Mass Index (kg/m^2)(Baseline (Day 0) and Close-out (16 weeks))
  • Anxiety(Baseline (Day 0) and Close-out (16 weeks))
  • Functional impairment due to dyspnea(Weekly for 16 weeks)
  • Medical treatment(Baseline (Day 0) and Close-out (16 weeks))
  • Hospitalization records(Baseline (Day 0) and Close-out (16 weeks))
  • Study device usability(Close-out (16 week))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Joseph C. Kvedar

Dermatologist

Massachusetts General Hospital

研究点 (1)

Loading locations...

相似试验